Traverse Biotech, Inc.

Poster presentation on TB-Bs1's therapeutic potential in ROR2 positive cancers at SITC 2024 NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Traverse Biotech, Inc., a privately held biotechnology company specializing in innovative immunotherapy solutions, today announced that it will present a poster at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, TX. The presentation will showcase preclinical results on TB-Bs1, Traverse's T-cell engaging product candidate targeting ROR2-positive solid tumors. Poster Presentation Details: Title: ROR2-targeted T-cell engager as a novel therapeutic approach in solid tumors Abstract Number: 1065 Location: Exhibit Halls A-B, George R. Brown Convention Center Date: Friday, November 8, 2024 Attending from Traverse Biotech: Brandy Houser, Ph.D., Co-Founder & Chief Executive Officer Jing Gong, Ph.D., Director of Strategy and Operations About TB-Bs1 TB-Bs1 is a first-in-class T-cell Engaging (TCE) bispecific antibody built on the DuoBody™ platform targeting ROR2. ROR2 is a receptor that has been shown to cause cancer cell proliferation and that has also been identified as a negative prognostic indicator. ROR2 is a member of the receptor tyrosine kinase-like orphan receptor family associated with Wnt signaling. We and others have confirmed ROR2 protein expression in liquid and solid cancers, with TB-Bs1 demonstrating consistent cytotoxic activity against ROR2-positive cancer cell lines. In a humanized mouse model, TB-Bs1 significantly inhibited tumor growth in a dose-dependent manner with minimal adverse effects. These results highlight the potential of TB-Bs1 as a targeted immunotherapy for ROR2-positive cancers. About Traverse Biotech Traverse Biotech, Inc. is a privately held US biotechnology company that is building a pipeline of innovative immunotherapy products from clinically validated platforms. Each product can reverse immune dysfunction in high unmet medical needs where the native immune system is unable to respond effectively. The Company licenses global commercialization rights for its products from selected biopharmaceutical companies in an original partnership model to accelerate therapeutic development to clinical proof-of-concept. Traverse's lean and flexible structure enables rapid clinical evaluation and cost reduction, ensuring faster patient access to novel therapies across selected diseases. For more information about Traverse Biotech, please visit or engage with us on LinkedIn. SOURCE Traverse Biotech WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, May 1, 2024 /PRNewswire/ -- Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. This grant will support the development of our oral innate immunotherapy stimulant modality with an emphasis on the evaluation of monocytic cellular activation using pathogen-associated molecular patterns (PAMPs) motifs. Brandy Houser, co-Founder and CEO of Traverse Biotech, expressed: "We are grateful for the support of NIAID. We believe that our product candidate has broad applicability to several immunological pathologies where myeloid derived cells are dysfunctional and ultimately not effective in disease resolution." This work will be conducted in collaboration with Dr. Sara Lustigman, Head of Molecular Parasitology at Lindsley F. Kimball Research Institute of New York Blood Center Enterprises. Dr. Lustigman's extensive academic research in immunology and infectious diseases will enable the evaluation of Traverse's innate immune stimulator mechanism of action in validated preclinical pathogenic models. About Traverse Biotech, Inc. is a privately held US biotechnology company that develops innovative immunotherapy products. Traverse Biotech focuses on late-stage preclinical and early clinical development of product candidates derived from de-risked technology platforms. For each product within its pipeline, Traverse licenses worldwide commercialization rights from selected international biopharma companies that are divesting promising product candidates due to strategic portfolio rationalization. Via an original partnership model, Traverse Biotech accelerates therapeutic development of each asset through clinical proof-of-concept. Its flexible and lean operating structure enables rapid clinical evaluation and cost reduction around all aspects of product development reaching patients sooner. SOURCE Traverse Biotech